IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 137.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,657 shares of the company's stock after purchasing an additional 31,626 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd owned 0.05% of Intellia Therapeutics worth $637,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the company. Regeneron Pharmaceuticals Inc. bought a new stake in Intellia Therapeutics during the 4th quarter valued at $43,177,000. Contrarius Group Holdings Ltd bought a new stake in Intellia Therapeutics in the 4th quarter worth about $11,798,000. State Street Corp increased its position in shares of Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company's stock valued at $105,700,000 after acquiring an additional 780,754 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Intellia Therapeutics by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock worth $118,816,000 after purchasing an additional 562,249 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Intellia Therapeutics during the 4th quarter worth $4,793,000. 88.77% of the stock is currently owned by institutional investors.
Intellia Therapeutics Trading Up 11.8 %
Shares of NTLA traded up $0.78 during midday trading on Wednesday, reaching $7.44. The stock had a trading volume of 2,629,545 shares, compared to its average volume of 2,226,582. The company has a market capitalization of $770.48 million, a price-to-earnings ratio of -1.37 and a beta of 1.97. The company's 50-day moving average is $9.86 and its 200 day moving average is $13.52. Intellia Therapeutics, Inc. has a 12-month low of $6.53 and a 12-month high of $28.18.
Analyst Ratings Changes
Several analysts have commented on NTLA shares. Chardan Capital lowered their price objective on shares of Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Oppenheimer decreased their target price on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research report on Monday, January 13th. Truist Financial lowered their target price on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. BMO Capital Markets cut their price target on Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research note on Friday, January 10th. Finally, Morgan Stanley cut Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $37.56.
Check Out Our Latest Research Report on NTLA
Insider Buying and Selling at Intellia Therapeutics
In other news, CEO John M. Leonard sold 26,807 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 29,000 shares of company stock worth $352,551 over the last ninety days. Insiders own 3.20% of the company's stock.
Intellia Therapeutics Company Profile
(
Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Further Reading
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
